Upregulation of Tim‐3 is associated with poor prognosis in acute myeloid leukemia
Cancer Medicine · 2023-04 · 12 (7) · 8956-8969
DOI: 10.1002/cam4.5549 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 21.12.2022. Verfasst von Zhengwei Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Hepatitis A Virus Cellular Receptor 2, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Planning Project of Guangdong Province.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is a heterogeneous hematopoietic malignancy originated from leukemia stem cells (LSC). Emerging evidence suggests T‐cell immunoglobulin mucin‐3(Tim3) as surface marker for LSC. However, the clinical significance and biology of Tim‐3 in AML remain to be determined, especially those LSCs. In public AML databases as well as our data, we separated AML patients into Tim‐3 high and Tim‐3 low subsets using the X‐tile software and evaluated the associations between Tim‐3 and overall survival (OS) and disease‐free survival (DFS). The Cancer Genome Atlas (TCGA) cohort revealed that high Tim‐3 expression in leukemic cells was linked with poor prognosis (DFS: p = 0.018; OS: p = 0.041). Furthermore, multiple regression analysis shows that Tim‐3 was an independent factor for the prognosis (HR = 2.26, 95% CI = 1.15–4.44, p = 0.017). Validation cohort of public gene expression omnibus (GEO) confirmed that Tim‐3 was a prognostic candidate in AML. Besides, in our internal cohort, we also confirmed that over expression of Tim‐3 protein in LSC/LPC made poor prognosis in AML. Additionally, we revealed that the LSC markers AKR1C3 , CD34, and MMRN1 were upregulated in the Tim‐3 high group of TCGA. We found that the upregulated genes in the Tim‐3 high group were mainly enriched in immune response, cytokine binding and cell adhesion molecules, and JAK–STAT signaling pathway, by gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Collectively, we revealed that, for the first time, upregulation of Tim‐3 in LSCs at the level of gene and protein expression is associated with poor prognosis and the important biological feature of Tim‐3 of LSC in AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
ORCID-Profile: Zhengwei Wu
Förderung
- National Natural Science Foundation of China
- Science and Technology Planning Project of Guangdong Province
Zitieren
APA
Wu, Z., Ou, J., Liu, N., Wang, Z., Chen, J., Cai, Z., Liu, X., Yu, X., Dai, M., & Zhou, H. (2023). Upregulation of Tim‐3 is associated with poor prognosis in acute myeloid leukemia. Cancer Medicine, 12(7), 8956-8969. https://doi.org/10.1002/cam4.5549
Vancouver
Wu Z, Ou J, Liu N, Wang Z, Chen J, Cai Z, et al. Upregulation of Tim‐3 is associated with poor prognosis in acute myeloid leukemia. Cancer Medicine. 2023;12(7):8956-8969. doi:10.1002/cam4.5549
BibTeX
@article{Wu2023,
author = {Wu, Zhengwei and Ou, Jiawang and Liu, Nannan and Wang, Zhixiang and Chen, Junjie and Cai, Zihong and Liu, Xiaoli and Yu, Xiao and Dai, Min and Zhou, Hongsheng},
title = {Upregulation of Tim‐3 is associated with poor prognosis in acute myeloid leukemia},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {7},
pages = {8956--8969},
doi = {10.1002/cam4.5549}
}
EUVIMED